Arcturus Therapeutics to Present RNAi Data for Orphan Diseases Utilizing the LUNAR™ Technology Platform at BIOCOM's Global Life Science Partnering Conference

SAN DIEGO, Feb. 24, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc., a leading RNA medicines company pursuing rare diseases, today announced it will present at BIOCOM's Global Life Science Partnering Conference being held on February 26 and 27, 2014 at the Lodge in Torrey Pines, La Jolla, California.   In addition to providing an update on its flagship program targeting transthyretin (TTR)-mediated amyloidosis, Arcturus will present data for its proprietary LUNAR^TM delivery technology and UNA Chemistry (32 patents, USPTO granted).  Functional in vivo delivery data of distinct classes of RNA (small interfering RNA and messenger RNA), a multiple-dose rat toxicology study, and non-human primate data will also be presented.  The company presentation will be Wednesday, February 26, 2:00 PM.

(Logo: http://photos.prnewswire.com/prnh/20130531/MM24393LOGO)

"We are delighted to be selected as a presenter at BIOCOM's annual Global Life Science Partnering Conference bringing together key decision makers from the San Diego life science community along with leading pharmaceutical and biotech executives from across the globe," said Zachary Zimmerman, Ph.D., Arcturus' Chief Business Officer. "The BIOCOM event provides Arcturus another excellent venue to showcase our RNA therapeutic programs and enabling technologies as well as to make connections with influential business development professionals from the life science industry."

About Transthyretin (TTR)-Mediated Amyloidosis

Transthyretin (TTR)-mediated amyloidosis is a genetically mediated fatal disease caused by mutations in the TTR gene. Mutated TTR, which is mainly synthesized in the liver, causes errant amyloid proteins to aggregate and deposit, destroying body organs and tissue, such as the peripheral nerves and heart.  TTR-mediated polyneuropathy (FAP) affects approximately 10,000 people and TTR-mediated cardiomyopathy (FAC) affects at least 40,000 people with the mean survival of ~2.5 years.  With limited therapeutic options, there is a substantial unmet need for effective medicines for patients suffering from TTR-mediated diseases.

About Arcturus Therapeutics, Inc.

Founded in 2013 and based in San Diego, Arcturus Therapeutics is focused on RNA medicines for the treatment of rare diseases. Arcturus has developed a novel, potent and safe RNA Therapeutics platform called LUNAR^TM, a proprietary lipid-enabled delivery system for RNA medicines including small interfering RNA, messenger RNA, antisense, and microRNA oligotherapeutics.  The company owns Unlocked Nucleic Acid (UNA) chemistry technology and patent portfolio (32 patents, USPTO granted) enabling the targeting of any gene in the human genome. For more information, visit www.ArcturusRx.com.

SOURCE Arcturus Therapeutics